Cargando…

Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?—a population-level analysis

BACKGROUND: Androgen deprivation therapy (ADT), commonly delivered via a luteinizing hormone-releasing hormone (LHRH) agonist, is the standard treatment for advanced prostate cancer (PC). While quite effective, it has been associated with an increased risk of major adverse cardiovascular events (MAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dymanus, Kyle, Friedrich, Nadine A., Howard, Lauren E., Oyekunle, Taofik, De Hoedt, Amanda M., Labadzhyan, Artak, Polascik, Thomas, Klaassen, Zachary, Freedland, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643384/ https://www.ncbi.nlm.nih.gov/pubmed/37969776 http://dx.doi.org/10.21037/tau-23-114

Ejemplares similares

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Androgen deprivation therapy and side effects: are GnRH antagonists safer?
por: Freedland, Stephen J, et al.
Publicado: (2020)

A modeling study to estimate prostate cancer‐specific mortality on active surveillance for men with favorable intermediate‐risk prostate cancer: Results from the SEARCH cohort
por: Kuhlmann, Paige K., et al.
Publicado: (2023)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy
por: Kelkar, Sonia, et al.
Publicado: (2021)

Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men
por: Vidal, Adriana C., et al.
Publicado: (2019)

Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study
por: Jenkins, Kimberly R., et al.
Publicado: (2021)

Estimated Costs and Long-term Outcomes of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System
por: Williams, Stephen B., et al.
Publicado: (2021)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
por: Cabarkapa, Sonja, et al.
Publicado: (2018)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

Thyrotoxicosis of pregnancy()
por: Labadzhyan, Artak, et al.
Publicado: (2014)

Tumor Androgen Receptor Protein Level Is Positively Associated with a Better Overall Survival in Melanoma Patients
por: Singh, Nupur, et al.
Publicado: (2023)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Do follicles matter? Testing the effect of follicles on hair cortisol levels
por: Sergiel, Agnieszka, et al.
Publicado: (2020)

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
por: Polascik, Thomas J
Publicado: (2009)

Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?
por: Shakespeare, Thomas P, et al.
Publicado: (2016)

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study
por: Park, Jun Won, et al.
Publicado: (2018)

Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications
por: Álvarez-Maestro, Mario, et al.
Publicado: (2021)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Elevated suicide risk among patients with urologic malignancies: highlighting at-risk populations
por: Sayyid, Rashid K., et al.
Publicado: (2020)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Lacrimal sac adenocarcinoma managed with androgen deprivation
por: Abramson, David H., et al.
Publicado: (2020)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
por: Tomioka, Atsushi, et al.
Publicado: (2015)

Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
por: Singh, Jagtar, et al.
Publicado: (2020)

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
por: Wang, Alice, et al.
Publicado: (2021)

A Population-Level Analysis of the Protective Effects of Androgen Deprivation Therapy Against COVID-19 Disease Incidence and Severity
por: Lee, Kyung Min, et al.
Publicado: (2022)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_56ho7qveuetv0hvmk0gtppr31v